文献速递头颈与中枢神经肿瘤

新诊断胶质母细胞瘤创新治疗随机个体筛选试验中外部对照数据的疗效再分析

Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data.
PubMed 文献 · J Clin Oncol · 2026-05-22

该研究对INSIGhT随机II期平台试验的三个实验组(abemaciclib、neratinib、CC-115)进行再分析,利用倾向性评分匹配从多个真实世界和临床试验数据集提取外部对照,比较基于内部对照与匹配外部对照的治疗效应估计。匹配外部对照后,三个实验组均未显示生存获益,HR分别为1.00、0.93和0.88,与先前基于内部对照的分析结果相似。模拟分析评估了整合外部对照的试验设计的效率与风险,结论认为该方法的有效性和偏倚风险取决于所有潜在混杂因素数据的完整性和准确性,且需不存在未测量混杂。

要点

  • 匹配外部对照后,abemaciclib、neratinib和CC-115均未显示生存获益。
  • 外部对照得到的治疗效应估计与内部对照分析结果相似。
  • 该方法有效性依赖于全面准确测量所有潜在混杂因素且无未测量混杂。

核心结论

  • 使用精心匹配的外部对照替代或补充INSIGhT内部对照,产生的治疗效应估计与先前发表的分析相似。
  • 单臂试验设计和整合倾向性评分匹配外部对照的混合随机设计可用于新诊断胶质母细胞瘤实验性疗法的早期疗效评估。
  • 该方法的有效性和偏倚风险取决于所有潜在混杂因素数据的全面准确,且需不存在未测量混杂。

研究设计与样本

  • 对INSIGhT随机II期平台试验的三个实验组进行再分析,该试验针对新诊断O6-甲基鸟嘌呤-DNA甲基转移酶未甲基化胶质母细胞瘤。
  • 实验组为abemaciclib(n=72)、neratinib(n=80)和CC-115(n=12),内部对照为标准放化疗(n=70)。
  • 从多个真实世界和临床试验数据集提取外部对照患者级数据,采用倾向性评分匹配和Cox比例风险模型估计治疗效应。
  • 利用该胶质母细胞瘤数据集合设定模拟场景,评估整合外部对照的试验设计。

主要发现

  • 与内部对照相比,三个实验组均未改善生存。
  • 匹配外部对照后,abemaciclib组HR为1.00(95% CI, 0.75至1.34)。
  • 匹配外部对照后,neratinib组HR为0.93(95% CI, 0.70至1.24)。
  • 匹配外部对照后,CC-115组HR为0.88(95% CI, 0.41至1.88)。

临床怎么用

  • 在胶质母细胞瘤早期试验中,可考虑采用单臂设计或整合倾向性评分匹配外部对照的混合随机设计评估治疗效应。
  • 应用外部对照方法时需确保所有潜在混杂因素数据全面准确,并评估未测量混杂的风险。

局限性

  • 该方法的有效性和偏倚风险取决于所有潜在混杂因素数据的全面准确,且需不存在未测量混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Integrating external control data into clinical trial designs and analyses has the potential to accelerate drug development processes. We reanalyzed the three experimental arms of the Individual Screening Trial of Innovative Glioblastoma Therapy (INSIGhT), a randomized phase II platform trial in newly diagnosed O6-methylguanine-DNA methyltransferase-unmethylated glioblastoma (ClinicalTrials.gov identifier: NCT02977780). To evaluate the validity of using external data sets, we compared treatment effect estimates based on internal INSIGhT control data and matched external control data. METHODS: The three experimental arms of INSIGhT (abemaciclib [n = 72], neratinib [n = 80], and CC-115 [n = 12]) did not improve survival compared with internal controls (standard chemoradiation [n = 70]). We derived external control patient-level data from multiple real-world and clinical trial data sets. We applied propensity score matching and Cox proportional hazards models to estimate treatment effects with external controls. Additionally, using this glioblastoma (GBM) data collection, we specified simulation scenarios to evaluate trial designs that integrate external controls. RESULTS: After matching to external controls, no survival benefit was observed for patients receiving abemaciclib (hazard ratio [HR], 1.00 [95% CI, 0.75 to 1.34]), neratinib (HR, 0.93 [95% CI, 0.70 to 1.24]), or CC-115 (HR, 0.88 [95% CI, 0.41 to 1.88]). Simulations, together with the INSIGhT data and a collection of GBM data sets, allowed us to examine efficiencies and risks of clinical trial designs that leverage external control data. CONCLUSION: The use of carefully matched external controls, to replace or augment the internal controls of INSIGhT, produced treatment effect estimates that were similar to previously published analyses. Single-arm trial designs and hybrid randomized designs incorporating propensity score-matched external control data evaluated treatment effects in the early-phase testing of experimental therapies in newly diagnosed GBM. The validity of this approach and risks of bias depended on the availability of comprehensive and accurate data on all potential confounders, in the absence of unmeasured confounding.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Rudra Gupta T, Polley MC, Redd R, et al. Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data. J Clin Oncol. 2026. PMID: 42172567. doi:10.1200/JCO-25-01586

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。